Efficacy, safety, and mitochondrial mechanisms of myricetin in a preclinical model of trastuzumab-resistant HER2+ breast cancer
{{output}}
Trastuzumab resistance remains a major clinical barrier in the treatment of HER2-positive breast cancer. To identify therapeutic candidates capable of overcoming resistance, we established trastuzumab-resistant derivatives of SKBR3 and BT474 cells and performe... ...
